{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:33:05Z","timestamp":1780392785783,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13555-025-01341-1","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T08:40:14Z","timestamp":1737794414000},"page":"337-350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Ersilia","family":"Tolino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-7709","authenticated-orcid":false,"given":"Luca","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Skroza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Potenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"1341_CR1","doi-asserted-by":"crossref","unstructured":"Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18(2):82\u201391.","DOI":"10.2310\/6620.2007.06034"},{"issue":"3 Suppl","key":"1341_CR2","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.sder.2012.07.006","volume":"31","author":"CN Ellis","year":"2012","unstructured":"Ellis CN, Mancini AJ, Paller AS, Simpson EL, Eichenfield LF. Understanding and managing atopic dermatitis in adult patients. Semin Cutan Med Surg. 2012;31(3 Suppl):S18\u201322.","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"1341_CR3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.alit.2021.07.003","volume":"71","author":"Y Tokura","year":"2022","unstructured":"Tokura Y, Hayano S. Subtypes of atopic dermatitis: from phenotype to endotype. Allergol Int. 2022;71(1):14\u201324.","journal-title":"Allergol Int"},{"issue":"1","key":"1341_CR4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3390\/ijms24010781","volume":"24","author":"K Makowska","year":"2023","unstructured":"Makowska K, Nowaczyk J, Blicharz L, et al. Immunopathogenesis of atopic dermatitis: focus on interleukins as disease drivers and therapeutic targets for novel treatments. Int J Mol Sci. 2023;24(1):781.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1341_CR5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","volume":"20","author":"P Facheris","year":"2023","unstructured":"Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20(5):448\u201374.","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"1341_CR6","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.3390\/ijms22084130","volume":"22","author":"J Sroka-Tomaszewska","year":"2021","unstructured":"Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22(8):4130.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1341_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2021.11.006","volume":"71","author":"T Yoshida","year":"2022","unstructured":"Yoshida T, Beck LA, De Benedetto A. Skin barrier defects in atopic dermatitis: from old idea to new opportunity. Allergol Int. 2022;71(1):3\u201313.","journal-title":"Allergol Int"},{"issue":"3","key":"1341_CR8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.16934","volume":"180","author":"T Tsakok","year":"2019","unstructured":"Tsakok T, Woolf R, Smith CH, Weidinger S, Flohr C. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2019;180(3):464\u201374.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1341_CR9","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/ijms21082867","volume":"21","author":"G Yang","year":"2020","unstructured":"Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. Int J Mol Sci. 2020;21(8):2867.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1341_CR10","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jaci.2018.01.019","volume":"141","author":"H Baurecht","year":"2018","unstructured":"Baurecht H, R\u00fchlemann MC, Rodr\u00edguez E, et al. Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. J Allergy Clin Immunol. 2018;141(5):1668\u20131676.e16.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1341_CR11","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.3390\/ijms23073503","volume":"23","author":"D Hrestak","year":"2022","unstructured":"Hrestak D, Matija\u0161i\u0107 M, \u010cip\u010di\u0107 Paljetak H, Ledi\u0107 Drvar D, Ljubojevi\u0107 Had\u017eavdi\u0107 S, Peri\u0107 M. Skin microbiota in atopic dermatitis. Int J Mol Sci. 2022;23(7):3503.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1341_CR12","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/ijms23052684","volume":"23","author":"L Fania","year":"2022","unstructured":"Fania L, Moretta G, Antonelli F, et al. Multiple roles for cytokines in atopic dermatitis: from pathogenic mediators to endotype-specific biomarkers to therapeutic targets. Int J Mol Sci. 2022;23(5):2684.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1341_CR13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","volume":"132","author":"M Su\u00e1rez-Fari\u00f1as","year":"2013","unstructured":"Su\u00e1rez-Fari\u00f1as M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361\u201370.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1341_CR14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","volume":"130","author":"JK Gittler","year":"2012","unstructured":"Gittler JK, Shemer A, Su\u00e1rez-Fari\u00f1as M, et al. Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344\u201354.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1341_CR15","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","volume":"139","author":"T Bieber","year":"2017","unstructured":"Bieber T, D\u2019Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immuno. 2017;139(4):S58\u201364.","journal-title":"J Allergy Clin Immuno"},{"key":"1341_CR16","volume":"103","author":"CO Park","year":"2024","unstructured":"Park CO, Kim SM, Lee KH, Bieber T. Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review. EBioMedicine. 2024;103:105121.","journal-title":"EBioMedicine"},{"issue":"1","key":"1341_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1\u201311.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1341_CR18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","volume":"143","author":"A Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135\u201341.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1341_CR19","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/all.16108","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Kabashima K, Staumont-Salle D, et al. Targeting IL-13 with tralokinumab normalizes type\u00a02 inflammation in atopic dermatitis both early and at 2\u00a0years. Allergy. 2024;79(6):1560\u201372.","journal-title":"Allergy"},{"issue":"3","key":"1341_CR20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase\u00a0III trials (ECZTRA\u00a01 and ECZTRA\u00a02). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1341_CR21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase\u00a0III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450\u201363.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1341_CR22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Flohr C, Cork M, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase\u00a03 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023;159(6):596\u2013605.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1341_CR23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","volume":"87","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1341_CR24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.anai.2020.12.004","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Guttman-Yassky E, Gooderham M, et al. Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: a phase\u00a02b randomized study. Ann Allergy Asthma Immunol. 2021;126(5):576\u2013583.e4.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1341_CR25","doi-asserted-by":"crossref","first-page":"2216815","DOI":"10.1080\/09546634.2023.2216815","volume":"34","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Vignoli CA, et al. Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. J Dermatolog Treat. 2023;34(1):2216815.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1341_CR26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40261-023-01258-7","volume":"43","author":"A De Greef","year":"2023","unstructured":"De Greef A, Ghislain PD, Bulinckx A, et al. Real-life experience of tralokinumab for the treatment of adult patients with severe atopic dermatitis: a multicentric prospective study. Clin Drug Investig. 2023;43(4):299\u2013306.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1341_CR27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/jvc2.296","volume":"3","author":"F Caroppo","year":"2024","unstructured":"Caroppo F, Belloni FA. Real-life case-series experience with tralokinumab in patients with severe atopic dermatitis. JEADV Clin Pract. 2024;3(1):296\u2013300.","journal-title":"JEADV Clin Pract"},{"key":"1341_CR28","doi-asserted-by":"crossref","unstructured":"Pezzolo E, Schena D, Gambardella A, et al. Survival, efficacy and safety of tralokinumab after 32 and 52\u2009weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. J Eur Acad Dermatol Venereol. 2024;38(1):e11\u2013e13.","DOI":"10.1111\/jdv.19382"},{"issue":"7","key":"1341_CR29","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamapediatrics.2017.0556","volume":"171","author":"C Roduit","year":"2017","unstructured":"Roduit C, Frei R, Depner M, et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 2017;171(7):655\u201362.","journal-title":"JAMA Pediatr"},{"issue":"4","key":"1341_CR30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/ACI.0000000000000837","volume":"22","author":"C Patruno","year":"2022","unstructured":"Patruno C, Potestio L, Napolitano M. Clinical phenotypes of adult atopic dermatitis and related therapies. Curr Opin Allergy Clin Immunol. 2022;22(4):242\u20139.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"1341_CR31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jdv.18008","volume":"36","author":"AL Bosma","year":"2022","unstructured":"Bosma AL, Ascott A, Iskandar R, et al. Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics. J Eur Acad Dermatol Venereol. 2022;36(6):807\u201319.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1341_CR32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/14712598.2023.2224499","volume":"23","author":"N Gori","year":"2023","unstructured":"Gori N, Ippoliti E, Peris K, Chiricozzi A. Head and neck atopic dermatitis: still a challenging manifestation in the biologic era. Expert Opin Biol Ther. 2023;23(7):575\u20137.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"1341_CR33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1159\/000519361","volume":"238","author":"A Chiricozzi","year":"2022","unstructured":"Chiricozzi A, Gori N, Di Nardo L, et al. Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients. Dermatology. 2022;238(4):717\u201324.","journal-title":"Dermatology"},{"issue":"11","key":"1341_CR34","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/exd.14368","volume":"30","author":"S Ribero","year":"2021","unstructured":"Ribero S, Puglisi B, Giura MT, et al. Head and neck severity index is associated to a significant worsening of quality of life in atopic dermatitis patients. Exp Dermatol. 2021;30(11):1717\u20138.","journal-title":"Exp Dermatol"},{"issue":"4","key":"1341_CR35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.det.2024.06.002","volume":"42","author":"LR Port","year":"2024","unstructured":"Port LR, Brunner PM. Management of atopic hand dermatitis. Dermatol Clin. 2024;42(4):619\u201323.","journal-title":"Dermatol Clin"},{"issue":"2","key":"1341_CR36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jaad.2023.04.056","volume":"89","author":"E Pezzolo","year":"2023","unstructured":"Pezzolo E, Gambardella A, Guanti M, et al. Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: a multicenter, prospective, open-label case series study. J Am Acad Dermatol. 2023;89(2):430\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1341_CR37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.clindermatol.2017.03.007","volume":"35","author":"NB Silverberg","year":"2017","unstructured":"Silverberg NB. Typical and atypical clinical appearance of atopic dermatitis. Clin Dermatol. 2017;35(4):354\u20139.","journal-title":"Clin Dermatol"},{"key":"1341_CR38","doi-asserted-by":"publisher","unstructured":"Baffa ME, Pipit\u00f2 C, Montefusco F, et al. Tralokinumab efficacy in a case of dupilumab-resistant severe atopic dermatitis complicated by eczema herpeticum. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19091.","DOI":"10.1111\/jdv.19091"},{"issue":"3","key":"1341_CR39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.anai.2022.05.029","volume":"129","author":"DYM Leung","year":"2022","unstructured":"Leung DYM, Ong PY. Dupilumab nonresponders in atopic dermatitis. Ann Allergy Asthma Immunol. 2022;129(3):267\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1341_CR40","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.abd.2023.09.009","volume":"99","author":"P Amoedo","year":"2024","unstructured":"Amoedo P, Rosa G, Baudrier T, Pedrosa AF, Cruz MJ. Atopic dermatitis: real-life experience with tralokinumab after dupilumab failure: a case series. An Bras Dermatol. 2024;99:721.","journal-title":"An Bras Dermatol"},{"issue":"3","key":"1341_CR41","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100519","volume":"14","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Thomsen SF, Lacour JP, Jaumont X, Lazarewicz S. Targeting immunoglobulin\u00a0E in atopic dermatitis: a review of the existing evidence. World Allergy Organ J. 2021;14(3):100519.","journal-title":"World Allergy Organ J"},{"issue":"6","key":"1341_CR42","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.21867","volume":"187","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase\u00a0II and phase\u00a0III trials. Br J Dermatol. 2022;187(6):888\u201399.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1341_CR43","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jech-2019-213435","volume":"74","author":"A H\u00f6hn","year":"2020","unstructured":"H\u00f6hn A, Gampe J, Lindahl-Jacobsen R, Christensen K, Oksuyzan A. Do men avoid seeking medical advice? A register-based analysis of gender-specific changes in primary healthcare use after first hospitalisation at ages 60+ in Denmark. J Epidemiol Community Health (1978). 2020;74(7):573\u20139.","journal-title":"J Epidemiol Community Health (1978)"},{"issue":"17","key":"1341_CR44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12875-016-0440-0","volume":"31","author":"AE Thompson","year":"2016","unstructured":"Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. BMC Fam Pract. 2016;31(17):38.","journal-title":"BMC Fam Pract"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01341-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01341-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01341-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:11:04Z","timestamp":1739837464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01341-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1341"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01341-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ersilia Tolino, Luca Ambrosio, Nicoletta Bernardini, Ilaria Proietti, Nevena Skroza and Concetta Potenza have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}